Antibacterial (Triclosan-Coated) Versus Conventional Sutures in Septoplasty
NCT07919496, Not applicable, Completed, Sakarya University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Antibacterial (Triclosan-Coated) Versus Conventional Sutures in Septoplasty | ClinicalTrials.gov |
| NCT number | NCT07919496 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 142 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Sakarya University | ClinicalTrials.gov |
| Conditions | Nasal Septal Deviation, Surgical Wound Healing, Surgical Site Infection | ClinicalTrials.gov |
| Interventions | Triclosan-Coated Polyglactin 910 Suture, Conventional Polyglactin 910 Suture | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Mucosal Healing Grade at the Septal Incision | Postoperative day 7 and postoperative day 21 | Healing of the septal incision and mucosal flaps assessed by nasal endoscopy and anterior rhinoscopy by an assessor masked to group allocation, graded as 1 = normal, 2 = delayed, 3 = inflamed healing. Lower grades indicate better healing. | ClinicalTrials.gov |
| Primary | Number of Participants With Clinical Signs of Surgical Site Infection | Postoperative day 7 and postoperative day 21 | Presence of local edema, erythema, purulent or serous discharge, or tissue tenderness at the operated septum, recorded as present or absent by an assessor masked to group allocation. | ClinicalTrials.gov |
| Primary | Postoperative Pain Intensity on a Visual Analogue Scale (VAS) | Postoperative day 7 and postoperative day 21 | Pain rated by the participant on a 0-10 visual analogue scale (0 = no pain, 10 = unbearable pain). Higher scores indicate worse pain. | ClinicalTrials.gov |
| Primary | Overall Postoperative Comfort Score | Postoperative day 7 and postoperative day 21 | Overall comfort rated by the participant on a 5-point Likert scale (range 1-5) in a structured face-to-face interview. Higher scores indicate greater comfort. | ClinicalTrials.gov |
| Secondary | Edema Score at the Surgical Site | Postoperative day 7 and postoperative day 21 | Edema at the septal incision graded by nasal endoscopy by a masked assessor as 0 = none, 1 = mild, 2 = moderate, 3 = severe. Higher scores indicate more edema. | ClinicalTrials.gov |
| Secondary | Number of Participants With Septal Hematoma | Postoperative day 7 and postoperative day 21 | Presence of septal hematoma on endoscopic examination, recorded as present or absent. | ClinicalTrials.gov |
| Secondary | Suture-Site Reaction | Postoperative day 7 and postoperative day 21 | Reaction at the suture line on endoscopic examination, categorized as none, erythema, granulation tissue or wound dehiscence (number of participants in each category). | ClinicalTrials.gov |
| Secondary | Suture Material Status | Postoperative day 7 and postoperative day 21 | Status of the suture material on endoscopic examination, categorized as in situ, broken or dislodged (number of participants in each category). | ClinicalTrials.gov |
| Secondary | Nasal Obstruction Symptom Evaluation (NOSE) Score | Postoperative day 7 and postoperative day 21 | Validated Turkish version of the NOSE scale: five items scored 0-4, raw total 0-20. Higher scores indicate worse nasal obstruction. | ClinicalTrials.gov |
| Secondary | Relief of Nasal Obstruction Score | Postoperative day 7 and postoperative day 21 | Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate greater relief of nasal obstruction. | ClinicalTrials.gov |
| Secondary | Intranasal Pressure Sensation Score | Postoperative day 7 and postoperative day 21 | Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate a more favourable status (less intranasal pressure sensation). | ClinicalTrials.gov |
| Secondary | Return to Activities of Daily Living Score | Postoperative day 7 and postoperative day 21 | Rated by the participant on a 5-point Likert scale (range 1-5). Higher scores indicate an easier return to daily activities. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)